Protective effect of erythropoietin against myocardial injury in rats with sepsis and its underlying mechanisms

Zhang,Xinliang; Dong,Shimin; Qin,Yanjun; Bian,Xiaohua

doi:10.3892/mmr.2015.3155

Protective effect of erythropoietin against myocardial injury in rats with sepsis and its underlying mechanisms

Authors:
- Xinliang Zhang
- Shimin Dong
- Yanjun Qin
- Xiaohua Bian
View Affiliations

Affiliations: Department of Emergency, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China, Department of Critical Care Medicine, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China
Published online on: January 8, 2015 https://doi.org/10.3892/mmr.2015.3155
Pages: 3317-3329
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the protective effect of erythropoietin (EPO) against acute myocardial injury and its underlying mechanisms. Mice (n=146) were randomly divided in a double‑blind manner into four groups, sham, Rocephin, EPO and sepsis, and mortality was observed on the seventh day after cecal ligation and puncture. In addition, a total of 252 rats were randomly divided into three groups, sham, EPO and sepsis, and indicators of cardiac function, inflammatory mediators and serum creatine kinase levels were assessed. Mitochondrial membrane potential, cell apoptosis and nuclear factor κ‑light‑chain‑enhancer of activated B cells (NF‑κB) p65 expression levels were detected using flow cytometry. Following intervention with EPO, the mortality rate in mice with sepsis was significantly reduced and the cardiac function of septic rats was significantly improved. In addition, the levels of inflammatory mediators, serum creatine kinase and apoptosis and the myocardial mitochondrial membrane potential and expression of NF‑κB p65 in cardiac tissue were all improved following EPO treatment, and the differences between the results for the sepsis and EPO groups were statistically significant (P<0.05). These findings suggest that EPO reduces the myocardial inflammatory response in septic rats, attenuates the reduction in mitochondrial membrane potential and inhibits myocardial cell apoptosis by reducing NF‑κB p65 expression, and therefore exerts a protective effect in the myocardium.

View Figures

View References

1	Levy MM, Fink MP, Marshall JC, et al: International Sepsis Definitions Conference: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 29:530–538. 2003. View Article : Google Scholar : PubMed/NCBI
2	Shimaoka M and Park EJ: Advances in understanding sepsis. Eur J Anaesthesiol Suppl. 42:146–153. 2008. View Article : Google Scholar : PubMed/NCBI
3	Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J and Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 29:1303–1310. 2001. View Article : Google Scholar : PubMed/NCBI
4	Dellinger RP, Carlet JM, Masur H, et al: Surviving Sepsis Campaign Management Guidelines Committee: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 32:858–873. 2004. View Article : Google Scholar : PubMed/NCBI
5	Meziani F, Tesse A and Andriantsitohaina R: Microparticles are vectors of paradoxical information in vascular cells including the endothelium: role in health and diseases. Pharmacol Rep. 60:75–84. 2008.PubMed/NCBI
6	Tetta C, Fonsato V, Ronco C and Camussi G: Recent insights into the pathogenesis of severe sepsis. Crit Care Resusc. 7:32–39. 2005.
7	Silva E, da Passos RH, Ferri MB and de Figueiredo LF: Sepsis: from bench to bedside. Clinics (Sao Paulo). 63:109–120. 2008. View Article : Google Scholar
8	Cinel I and Dellinger RP: Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis. 20:345–352. 2007. View Article : Google Scholar : PubMed/NCBI
9	Tramontano AF, Muniyappa R, Black AD, et al: Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun. 308:990–994. 2003. View Article : Google Scholar : PubMed/NCBI
10	Maiese K, Li F and Chong ZZ: Erythropoietin in the brain: can the promise protect be fulfilled? Trends Pharmacol Sci. 25:577–583. 2004. View Article : Google Scholar : PubMed/NCBI
11	Juul SE, Yachnis AT and Chistensen RD: Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev. 52:235–249. 1998. View Article : Google Scholar : PubMed/NCBI
12	Cai Z, Manalo DJ, Wei G, et al: Hearts from rodents exposed to intermittent hypoxia orerythropoietin are protected against ischemia-reperfusion injury. Circulatio. 108:79–85. 2003. View Article : Google Scholar
13	Aoshiba K, Onizawa S, Tsuji T and Nagai A: Therapeutic effects of erythropoietin in murine models ofendotoxin shock. Crit Care Med. 37:889–898. 2009. View Article : Google Scholar : PubMed/NCBI
14	Bemardi P, Scorrano L, Colonna R, Petronilli V and Di Lisa F: Mitochondria and cell death. Mechanistic aspects and methodological issues. Eur J Biochem. 264:687–701. 1999. View Article : Google Scholar
15	Tan C, Dlugosz PJ, Peng J, et al: Auto-activation of the apoptosis protein Bax increases mitochondrial membrane permeability and is inhibited by BCL-2. J Biol Chem. 281:14764–14775. 2006. View Article : Google Scholar : PubMed/NCBI
16	Germ DR and Reed JC: Mitochondria and apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar
17	Nechushtan A, Smith CL, Lamensdorf I, Yoon SH and Youle RJ: Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J Cell Biol. 153:1265–1276. 2001. View Article : Google Scholar : PubMed/NCBI
18	Dschietzig T, Richter C, Pfannenschmidt G, et al: Dexamethasone inhibits stimulation of pulmonary endothelins by proinflammatory cytokines: possible involvement of a nuclear factor kappa B dependent mechanism. Intensive Care Med. 27:751–756. 2001. View Article : Google Scholar : PubMed/NCBI
19	Yinjun L, Jie J and Yungui W: Triptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cells. Leuk Res. 29:99–105. 2005. View Article : Google Scholar
20	Wichterman KA, Baue AE and Chaudry IH: Sepsis and septic shock - a review of laboratory models and a proposal. J Surg Res. 29:189–201. 1980. View Article : Google Scholar : PubMed/NCBI
21	Telford WG, King LE and Fraker PJ: Comparative evaluation of several DNA binding dyes in the detection of apoptosia-associated chromatin degradation by flow cytometry. Cytometry. 13:137–143. 1992. View Article : Google Scholar
22	Gurkan F, Alkaya A, Ece A, et al: Cardiac troponin-I as a marker of myocardial dysfunction in children with septic shock. Swiss Med Wkly. 134:593–596. 2004.PubMed/NCBI
23	ver Elst KM, Spapen HD, Nguyen DN, Garbar C, Huyghens LP and Gorus FK: Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin Chem. 46:650–657. 2000.PubMed/NCBI
24	Turner A, Tsamitros M and Bellomo R: Myocardial cell injury in septic shock. Crit Care Med. 27:1775–1780. 1999. View Article : Google Scholar : PubMed/NCBI
25	Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 339:584–590. 1998. View Article : Google Scholar : PubMed/NCBI
26	Phrommintikul A, Haas SJ, Elsik M and Krum H: Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 369:381–388. 2007. View Article : Google Scholar : PubMed/NCBI
27	Zarychanski R, Turgeon AF, McIntyre L and Fergusson DA: Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. CMAJ. 177:725–734. 2007. View Article : Google Scholar : PubMed/NCBI
28	Arcasoy MO: The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 141:14–31. 2008. View Article : Google Scholar : PubMed/NCBI
29	Bohlius J, Wilson J, Seidenfeld J, et al: Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 3:CD0034072006.PubMed/NCBI